Targeting leukemia cells to improve treatment outcomes
Pharmacodynamically directed targeted therapy for leukemia
This study is looking for better ways to treat Acute Myeloid Leukemia (AML) by creating new drugs that can specifically attack leukemia cells and boost the immune system, which could help patients live longer and have better treatment results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-11130087 on NIH RePORTER |
What this research studies
This research focuses on improving therapies for Acute Myeloid Leukemia (AML), a severe form of leukemia that often relapses despite treatment. The team aims to develop new drugs that specifically target leukemia cells while enhancing the immune response against them. By inhibiting a key enzyme involved in cell growth, the research seeks to differentiate leukemia cells from normal blood cells, potentially leading to better treatment outcomes. Patients may benefit from a combination of these new therapies with existing treatments to improve survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with Acute Myeloid Leukemia, particularly those with TP53 mutations.
Not a fit: Patients with other types of leukemia or those who do not have Acute Myeloid Leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with Acute Myeloid Leukemia, potentially improving survival rates and reducing relapse.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in leukemia treatment, indicating potential for success with this novel approach.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Byrd, John C. — University of Cincinnati
- Study coordinator: Byrd, John C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.